The effect of chitosan supplementation in patients with nonalcoholic fatty liver disease (NAFLD)
- Conditions
- onalcoholic fatty liver.Nonalcoholic fatty liver disease [NAFLD]
- Registration Number
- IRCT20180412039284N1
- Lead Sponsor
- Ahvaz University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 50
Individuals of both genders (males and females) will be selected to participate in the study, aged between 18 and 65 years old that their fatty liver diagnosed by ultrasound testing
No allergies to seafood
Hepatitis, liver cirrhosis, Wilson's disease, acute fatty liver, pregnancy, hepatocellular carcinoma, hypothyroidism and chronic liver disease
Lipodystrophy
Menopause
Parenteral nutrition
Diseases that involve bile ducts and bile ducts
Severe weight loss (more than 10% of body weight) during last 6 months and weight loss surgery
Congenital metabolic diseases
Consumption of Herbal Supplements in the last three months
Taking drugs that cause fatty liver and liver toxicity (amiodarone, antivirals, spirin, non-steroidal anti-inflammatory drugs, corticosteroids, methotrexate, tamoxifen, tetracycline, valproic acid
Pregnancy and lactation
Consumption of Omega 3 and Vitamin E and other antioxidant supplements over the past 6 months
History of cardiovascular disease and kidney disease
BMI between 25 and 40
Unwillingness to participate
Energy consumption less than 800 or more than 4200kcal/day
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method